SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns:
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Julius Wong5/22/2024 11:42:40 PM
1 Recommendation

Recommended By
Return to Sender

   of 8262
 
Pfizer, Moderna in talks with HHS over avian flu vaccine: report (update)

May 22, 2024 6:09 PM ET
By: Val Brickates Kennedy, SA News Editor

carmengabriela

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) are reportedly in talks with the U.S. government over setting up a possible vaccine program aimed at combatting the spread of the H5N1 virus, also known as avian flu.

U.S. Department of Health and Human Services Assistant Secretary of Pandemic Preparedness Dawn O’Connell said on a call with reporters after market close on Wednesday that the department has been in discussions with both vaccine developers about producing mRNA-based vaccines to protect against avian flu, according to Barron’s.

O’Connell said negotiations with the vaccine makers are “ongoing” and that the agency was “hoping to wrap this up and have something to say very soon.” She added that HHS has been converting 4.8M doses of avian flu vaccine from the government’s bulk stockpile into finished doses.

The HHS assistant secretary added that converting the bulk vaccine into finished doses would take a “couple of months” and that the process shouldn’t interfere with vaccine production for the seasonal flu, Barron's said.

Earlier Wednesday, the U.S. Centers for Disease Control and Prevention said that while a second human case of avian flu had been reported in the U.S., the risk of the virus causing another pandemic was currently low.

Moderna confirmed to Seeking Alpha on Wednesday evening that it was in discussions with the government over a pandemic flu vaccine.

"Moderna can confirm we are in discussions with the U.S. Government on advancing our pandemic flu candidate, mRNA-1018. The Phase 1/2 dosing of mRNA-1018 is complete, with data expected soon," Moderna said in an emailed statement.

"The H5 vaccines in this trial cover the same clade as the currently circulating variant in the United States. We remain committed to using our mRNA platform to respond to public health concerns," Moderna added.

Barron’s noted that GSK ( GSK) and CSL Seqirus ( OTCQX:CSLLY) are also testing vaccines targeted at a strain of the H5N1 virus under a contract with the U.S. government. Sanofi ( SNY) is also involved in the project.

Pfizer and Moderna did not immediately comment on the matter, Barron’s said.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News